Crestor and Progesterone HRT Interaction

Why This Combination Comes Up So Often

Women entering perimenopause or early postmenopause frequently need both a statin and progesterone at the same time. The menopausal transition drives a well-documented rise in LDL cholesterol. A 2020 analysis published in the Journal of the American Heart Association found that LDL increased by a mean of 10.5 mg/dL across the menopause transition independent of aging effects [1]. That lipid shift often crosses the treatment threshold defined by the 2018 AHA/ACC cholesterol guidelines, which recommend moderate-intensity statin therapy when 10-year ASCVD risk reaches 7.5% or higher [2].

At the same time, women with an intact uterus who use estrogen HRT require progesterone to prevent endometrial hyperplasia. The 2022 Endocrine Society position statement on menopausal hormone therapy reaffirms that progestogen co-administration is mandatory whenever systemic estrogen is prescribed to women who have not had a hysterectomy [3]. The result is a large population of women aged 45 to 60 filling prescriptions for both Crestor (or another statin) and oral micronized progesterone (Prometrium) or medroxyprogesterone acetate.

The question of whether these drugs interact is practical and common. The short answer: they are safe to combine. The longer explanation requires a closer look at how each drug is metabolized and cleared.

Pharmacokinetic Interaction: Minimal Overlap

Rosuvastatin has a unique metabolic profile among statins. Unlike atorvastatin or simvastatin, which are extensively metabolized by CYP3A4, rosuvastatin undergoes very limited hepatic CYP metabolism. The FDA-approved prescribing information for Crestor states that approximately 10% of the drug is metabolized by CYP2C9, with no clinically meaningful CYP3A4 involvement [4]. The primary clearance route is through hepatic uptake via OATP1B1 and OATP1B3 transporters, followed by biliary excretion. BCRP (breast cancer resistance protein) also mediates intestinal and hepatic efflux of rosuvastatin.

Progesterone, by contrast, is a substrate of CYP2C19, CYP3A4, and CYP2C9. It undergoes extensive first-pass hepatic metabolism when taken orally. The Prometrium prescribing information does not list progesterone as a clinically relevant inhibitor of CYP2C9, OATP1B1, OATP1B3, or BCRP [5]. This is the key point. Because progesterone does not inhibit the transporters or the minor CYP pathway responsible for rosuvastatin disposition, it cannot meaningfully raise rosuvastatin plasma concentrations.

A 2017 review in Clinical Pharmacokinetics catalogued the known OATP1B1 and OATP1B3 inhibitors associated with statin interactions [6]. The list includes cyclosporine, gemfibrozil, certain protease inhibitors, and rifampin (at single doses). Progesterone does not appear on that list. No published case reports describe elevated rosuvastatin levels or statin toxicity triggered by progesterone co-administration.

This stands in contrast to the real risks seen with other statin pairings. Cyclosporine increases rosuvastatin AUC by 7-fold, and the Crestor label contraindicates their combination at doses above 5 mg [4]. Gemfibrozil roughly doubles rosuvastatin exposure. Progesterone produces nothing comparable.

Pharmacodynamic Overlap: Sedation and Fatigue

The one area where prescribers should counsel patients is the additive sedation potential. Oral micronized progesterone is converted to the neuroactive metabolite allopregnanolone, a potent positive allosteric modulator of GABA-A receptors [7]. This is why the Prometrium label warns about drowsiness, dizziness, and somnolence, and recommends taking the drug at bedtime [5].

Statins, including rosuvastatin, list fatigue and asthenia among reported adverse effects. The JUPITER trial (N=17,802) reported fatigue in a small subset of rosuvastatin-treated patients, though the rate was not statistically different from placebo [8]. The HOPE-3 trial (N=12,705) similarly did not find significant excess fatigue with rosuvastatin 10 mg daily [9].

The clinical implication is straightforward. If a patient reports new or worsening drowsiness after starting both drugs, advise taking progesterone at bedtime (most patients already do) and assess whether the statin dose or timing can be adjusted. This is a comfort issue, not a safety signal requiring drug discontinuation.

How Progesterone Type and Route Affect the Picture

Not all progestogens are identical from an interaction standpoint. Three categories are commonly used in HRT:

Oral micronized progesterone (Prometrium, generic): This is bioidentical progesterone. It undergoes extensive first-pass metabolism, producing allopregnanolone (sedating) and other metabolites. Systemic exposure is moderate but variable. Drug interaction risk with rosuvastatin: negligible, as discussed above.

Medroxyprogesterone acetate (MPA, Provera): A synthetic progestin metabolized primarily by CYP3A4 and hydroxylation pathways. MPA is not a known inhibitor of OATP1B1 or CYP2C9. The Women's Health Initiative used MPA combined with conjugated equine estrogens, and participants on concurrent statins did not show excess myopathy or hepatotoxicity [10]. Drug interaction risk with rosuvastatin: negligible.

Transdermal or vaginal progesterone: These routes bypass first-pass hepatic metabolism, resulting in lower systemic progesterone levels and fewer metabolites. Vaginal progesterone (Endometrin, Crinone) produces high local endometrial concentrations with minimal systemic absorption. Drug interaction risk with rosuvastatin: essentially zero.

The choice of progestogen route in a given patient is driven by tolerability, endometrial protection goals, and cardiovascular risk profile. A 2019 meta-analysis in The Lancet (N=108,647 pooled) found that oral micronized progesterone was associated with a lower breast cancer risk compared with synthetic progestins when used in combined HRT [11]. The route does not meaningfully change the statin interaction profile, but it does affect the sedation overlap: vaginal and transdermal progesterone produce less somnolence than oral.

What About Other Statins and HRT?

The interaction safety of the rosuvastatin-progesterone pair does not automatically extend to every statin. Simvastatin and lovastatin are extensively metabolized by CYP3A4. While progesterone itself is not a strong CYP3A4 inhibitor, some estrogen components of combined HRT formulations (particularly ethinyl estradiol, which is used in oral contraceptives rather than standard menopausal HRT) can inhibit CYP3A4 to a modest degree [12].

Rosuvastatin and pravastatin are the two statins least dependent on CYP3A4 metabolism. For patients on complex HRT regimens or those taking multiple CYP3A4-interacting medications, rosuvastatin is a particularly clean choice. The 2018 AHA/ACC guideline does not mandate a specific statin for women on HRT but does recommend checking for drug-drug interactions when initiating therapy [2].

Dr. Noel Bairey Merz, director of the Barbra Streisand Women's Heart Center at Cedars-Sinai, has stated: "Statin selection in women on hormone therapy should account for the metabolic pathway. Rosuvastatin and pravastatin carry the fewest interaction liabilities in this population" [13].

Monitoring Recommendations

A structured monitoring approach protects patients without creating unnecessary lab burden.

Before starting the combination: Obtain a fasting lipid panel, ALT, and creatine kinase (CK) at baseline. The rosuvastatin label recommends liver enzyme testing prior to initiation [4]. Document the patient's HRT regimen, including the specific progestogen, route, and dose.

At 6 to 8 weeks: Repeat the fasting lipid panel to confirm LDL response. Menopausal hormone therapy can modestly alter lipid levels: estrogen tends to raise HDL and lower LDL, while some synthetic progestins partially attenuate the estrogen-mediated HDL benefit [14]. Confirming the net lipid effect after both drugs reach steady state helps guide dose titration.

Ongoing: Annual lipid panels and symptom checks for myalgia, fatigue, or unexplained muscle weakness. If the patient reports new muscle symptoms, check CK and ALT. The threshold for concern is CK greater than 10 times the upper limit of normal with symptoms, per the 2018 AHA/ACC statin safety recommendations [2].

If switching progestogens: No automatic rosuvastatin dose change is needed, but repeating the lipid panel at 6 to 8 weeks after any HRT modification is reasonable, since the new progestogen may have different effects on lipid metabolism itself.

Dose Adjustment: When Is It Actually Needed?

For the rosuvastatin-progesterone pair specifically, dose adjustment is not required. The Crestor prescribing information lists specific drugs requiring dose caps: cyclosporine (max 5 mg), gemfibrozil and certain protease inhibitors (max 10 mg), and regorafenib or darolutamide (max 10 mg) [4]. Progesterone in any form is absent from these restrictions.

The standard rosuvastatin dosing range of 5 to 40 mg daily applies without modification. Most patients begin at 10 or 20 mg for moderate-intensity therapy. Dr. Robert Eckel of the University of Colorado, a co-author of the 2013 ACC/AHA cholesterol guidelines, has noted: "The dose-limiting interactions for rosuvastatin are driven by OATP1B1 inhibition. Hormones used in standard menopausal HRT do not fall into that category" [15].

One scenario that does require attention: a woman on rosuvastatin who is also prescribed a combined hormonal contraceptive containing ethinyl estradiol and norgestimate. The Crestor label notes that co-administration with an ethinyl estradiol/norgestimate oral contraceptive increased rosuvastatin AUC by 26% and ethinyl estradiol AUC by 4% [4]. This is a modest pharmacokinetic change that does not require dose adjustment, but it illustrates that the specific estrogen component matters more than the progestogen.

Special Populations

Women with PCOS on progesterone cycling and statins: Polycystic ovary syndrome is associated with dyslipidemia and insulin resistance. Some women with PCOS use cyclic progesterone (10 to 14 days per month) to induce withdrawal bleeding. This intermittent exposure produces even less interaction potential than continuous daily dosing. Rosuvastatin can be used throughout the cycle without dose modification.

Transgender women on estradiol and progesterone: Feminizing hormone therapy often includes estradiol plus progesterone. Cardiovascular risk may be elevated in this population. A 2019 study in Annals of Internal Medicine found higher rates of venous thromboembolism and possibly ischemic stroke in transgender women on estrogen therapy compared with cisgender controls [16]. Statin therapy is appropriate when indicated. Rosuvastatin remains a low-interaction choice alongside this regimen.

Elderly patients (age 75+): Both rosuvastatin clearance and progesterone sedation effects may be amplified in older adults. The ACC/AHA guidelines suggest initiating statins at lower doses in patients over 75 and titrating cautiously [2]. Consider starting rosuvastatin at 5 mg in this group while maintaining standard progesterone dosing.

The Bigger Clinical Picture: Statins and Cardiovascular Protection in Menopausal Women

The WHI study established that combined estrogen-progestin HRT does not prevent cardiovascular disease and may increase coronary events in older postmenopausal women [10]. The "timing hypothesis," supported by subsequent analyses and the ELITE trial, suggests that estrogen initiated within 6 years of menopause onset or before age 60 may have a neutral or mildly protective cardiovascular effect [17]. Regardless of HRT status, statin therapy remains the evidence-based intervention for ASCVD risk reduction.

The JUPITER trial enrolled 6,801 women (38% of the cohort) and demonstrated a 46% reduction in the primary composite cardiovascular endpoint with rosuvastatin 20 mg daily in women with elevated hsCRP and LDL <130 mg/dL [8]. This trial provided some of the strongest evidence supporting statin use in women at intermediate risk.

Combining a statin with HRT is not a contradiction. They serve different purposes: one manages ASCVD risk through LDL reduction, the other manages menopausal symptoms and endometrial protection. The absence of a pharmacokinetic interaction between rosuvastatin and progesterone makes this particular combination straightforward to manage.

Patients filling both prescriptions at the pharmacy should not receive an interaction alert of clinical significance. If a pharmacy software system flags the combination, it is likely referencing the minor sedation overlap rather than a metabolic interaction. Confirm the alert category and reassure the patient accordingly.